Format

Send to

Choose Destination
Haematologica. 2019 May 2. pii: haematol.2018.212597. doi: 10.3324/haematol.2018.212597. [Epub ahead of print]

Ibrutinib reduces obinutuzumab infusion related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.

Author information

1
UC San Diego Moores Cancer Center, San Diego, CA.
2
Mayo Clinic, Scottsdale, AZ.
3
Mayo Clinic, Scottsdale, AZ castro.januario@mayo.edu.

KEYWORDS:

Cell Therapy and Immunotherapy; Chronic Lymphocytic Leukemia; Cytokine release syndrome; Ibrutinib; Obinutuzumab

PMID:
31048356
DOI:
10.3324/haematol.2018.212597
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center